Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NETTER-3 trial of lutetium Lu 177 oxodotreotide in newly diagnosed advanced high-burden GEP-NET
CTR20252270Phase 3Active
- Sponsor
- Novartis
- Start
- Oct 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 3 trial of lutetium Lu 177 dotatate in Gastroenteropancreatic Carcinoid Tumor, sponsored by Novartis. Started Oct 2025; status: active.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on CTR20252270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252270.